4-甲氧基-2-萘胺 | 2764-95-6

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 4-甲氧基-2-萘胺
• 中文别名: 4-甲氧基2-氨基萘；4-甲氧基-2-氨基萘；4-甲氧基-β-萘胺
• 英文名称: 4-methoxy-2-naphthylamine
• 英文别名: 2-amino-4-methoxynaphthalene；4-methoxynaphthalen-2-amine；4-methoxy-[2]naphthylamine；4-Methoxy-[2]naphthylamin；4-methoxy-β-naphtylamine；3-amino-1-methoxynaphthalene
• CAS: 2764-95-6
• 化学式: C₁₁H₁₁NO
• mdl: MFCD00056592
• 分子量: 173.214
• InChiKey: SFKZPTYRENGBTJ-UHFFFAOYSA-N

物化性质

• 熔点：
  57.5-58.5 °C(Solv: ligroine (8032-32-4))
• 沸点：
  352.9±15.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090
• WGK Germany：
  3

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Methoxy-2-naphthylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Methoxy-2-naphthylamine
CAS number: 2764-95-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H11NO
Molecular weight: 173.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲氧基-2-萘胺 在 N-碘代丁二酰亚胺 、 水 、 氢溴酸 、 三正丁基氢锡 、 sodium hydride 、 caesium carbonate 、 对甲苯磺酸 、 溶剂黄146 、 lithium hydroxide 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 、 苯 为溶剂， 反应 37.58h， 生成 5-(benzyloxy)-3-(tert-butyloxycarbonyl)-1-(hydroxymethyl)-1,2-dihydro-3H-benzindole
  参考文献：
  名称：

  [EN] ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS
  [FR] DIMÈRES D'ISOQUINOLIDINOBENZODIAZÉPINE (IQB)-1(CHLOROMÉTHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI)

  摘要：

  本文提供了异喹啉苯二氮卓啶（IQB）-1（氯甲基）-2,3-二氢-1H-苯并[e]吲哚（CBI）二聚体，包括它们的抗体药物结合物，以及用于杀灭细胞和治疗疾病的方法。

  公开号：

  WO2018071455A1
• 作为产物：
  描述：

  间萘二酚 在 盐酸 、 氢氧化钾 、 potassium carbonate 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 4-甲氧基-2-萘胺
  参考文献：
  名称：

  The Coupling of 4-Methoxy-2-naphthylamine with Diazotized Aminodiazo Thioethers^*,1

  摘要：

  DOI：

  10.1021/jo01017a016

文献信息

• Substituted &bgr;-amino acid inhibitors of methionine aminopeptidase-2
  申请人：Abbott Laboratories

  公开号：US06242494B1

  公开（公告）日：2001-06-05

  A class of substituted b-amino acids are potent inhibitor of methionine aminopeptidase type 2 (MetAP2) and are thus useful in inhibiting angiogenesis and disease conditions which depend upon angiogenesis for their development such as diabetic retinopathy, tumor growth, and conditions of inflammation. Pharmaceutical compounds containing the compounds and methods of inhibiting methionine aminopeptidase-2, and angiogenesis are also disclosed.

  一类取代的β-氨基酸是对蛋氨酸氨基肽酶2（MetAP2）的强效抑制剂，因此在抑制依赖血管生成发展的疾病状况（如糖尿病视网膜病变、肿瘤生长和炎症状况）方面非常有用。还披露了包含这些化合物的药物化合物以及抑制蛋氨酸氨基肽酶-2和血管生成的方法。
• CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF
  申请人：Sufi Bilal

  公开号：US20100145036A1

  公开（公告）日：2010-06-10

  The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

  本公开提供了药物-配体共轭物和药物可切割底物共轭物，它们是有效的细胞毒素。该公开还涉及含有药物-配体共轭物的组合物，以及使用它们的治疗方法。
• Nitrile-containing enzyme inhibitors and ruthenium complexes thereof
  申请人：The Ohio State University Research Foundation

  公开号：US20140100173A1

  公开（公告）日：2014-04-10

  The invention provides nitrile-containing protease inhibitors caged to ruthenium compounds. The nitrile-caged ruthenium compounds provide inactivated inhibitors that can be delivered to surface or site for activation, for example, but exposure to light. The invention also provides methods for delivering protease inhibitors to subjects for the therapeutic treatment of conditions such as cancer.

  这项发明提供了与钌化合物结合的含腈基蛋白酶抑制剂。这些腈基蛋白酶抑制剂与钌化合物结合后形成失活的抑制剂，可以通过光照等方式被释放到表面或部位进行激活。该发明还提供了将蛋白酶抑制剂传递给受试者以治疗癌症等疾病的方法。
• Substituted 3-Amino-Pyrrolidino-4-Lactams
  申请人：Piotrowski David W.

  公开号：US20070299076A1

  公开（公告）日：2007-12-27

  The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R 1 , n and R 2 are as described herein; compositions thereof; and uses thereof.

  这项发明提供了式（1）的化合物，以及其药用可接受的盐，其中R1、n和R2如本文所述；以及它们的组合物；以及它们的用途。
• Dipeptidyl peptidase-IV inhibitors
  申请人：Hulin Bernard

  公开号：US20050234065A1

  公开（公告）日：2005-10-20

  The invention provides compounds of Formula (I) or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R 1 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.

  该发明提供了Formula (I)的化合物或其前药，或者该化合物或前药的药用可接受盐，或者该化合物、前药或盐的溶剂化合物，其中A、N、X和R1如本文所定义；以及这些药物组合物；以及使用这些药物组合物治疗疾病的方法，包括2型糖尿病、1型糖尿病、糖耐量受损、高血糖、代谢综合征（综合征X和/或胰岛素抵抗综合征）、葡萄糖尿病、代谢性酸中毒、关节炎、白内障、糖尿病神经病、糖尿病肾病、糖尿病视网膜病、糖尿病心肌病、肥胖、由肥胖恶化的疾病、高血压、高脂血症、动脉粥样硬化、骨质疏松症、脆弱、骨质流失、骨折、急性冠状动脉综合征、生长激素缺乏引起的矮小症、多囊卵巢综合征引起的不孕症、焦虑、抑郁、失眠、慢性疲劳、癫痫、进食障碍、慢性疼痛、酒精成瘾、与肠道蠕动相关的疾病、溃疡、肠易激综合征、炎症性肠病；短肠综合征；以及预防2型糖尿病疾病进展。